Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

BACKGROUND: Cetuximab and bevacizumab reportedly improve the survival of patients with metastatic colorectal cancer (mCRC), but their most effective sequence of administration is unknown. The aim of this study was to compare the survival of patients with mCRC treated with cetuximab after bevacizumab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Sato, Yasuyoshi, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2015
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648607/
https://ncbi.nlm.nih.gov/pubmed/26648737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S89241
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars